Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matt Herper joins us to pick apart the surprising news that Katrine Bosley, CEO of the CRISPR-focused Editas Medicine (EDIT), is quitting her job come March. Then, Matt sticks around to debate the legacy of Celgene (CELGZ), a storied pillar of biotech that will soon be consumed by Bristol-Myers Squibb. And then we’ll delve into an idea gaining traction in Silicon Valley: using genomic profiling to recommend cancer drugs for dogs. Finally, we’ll embark upon a lightning round, covering a biotech interrupted, a pair of Theranos documentaries, and a lot of money in Washington.

For more on what we cover, here’s the news on Editas; here’s Matt’s history of Celgene; here’s the dog genomics story; and here’s the latest on pharmaceutical lobbying.

advertisement

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email readoutloud@statnews.com.


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at marketing@statnews.com.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy